Origin of bistability underlying mammalian cell cycle entry.

Emerging biomedical applications of synthetic biology. Nat Rev Genet (2011) 2.05

Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer (2011) 1.51

Quantitative and logic modelling of molecular and gene networks. Nat Rev Genet (2015) 1.30

Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle (2011) 1.25

The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer (2015) 1.09

Start and the restriction point. Curr Opin Cell Biol (2013) 1.01

Bottom-up construction of in vitro switchable memories. Proc Natl Acad Sci U S A (2012) 1.01

Network topologies and dynamics leading to endotoxin tolerance and priming in innate immune cells. PLoS Comput Biol (2012) 1.00

Basal p21 controls population heterogeneity in cycling and quiescent cell cycle states. Proc Natl Acad Sci U S A (2014) 0.96

Optimization and model reduction in the high dimensional parameter space of a budding yeast cell cycle model. BMC Syst Biol (2013) 0.93

A characterization of scale invariant responses in enzymatic networks. PLoS Comput Biol (2012) 0.93

Synergistic and antagonistic drug combinations depend on network topology. PLoS One (2014) 0.92

Characterizing multistationarity regimes in biochemical reaction networks. PLoS One (2012) 0.88

An analytical approach to bistable biological circuit discrimination using real algebraic geometry. J R Soc Interface (2015) 0.86

Strategic cell-cycle regulatory features that provide mammalian cells with tunable G1 length and reversible G1 arrest. PLoS One (2012) 0.83

Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control. Nat Commun (2014) 0.83

A geometrical approach to control and controllability of nonlinear dynamical networks. Nat Commun (2016) 0.83

Tension and robustness in multitasking cellular networks. PLoS Comput Biol (2012) 0.82

Modelling mammalian cellular quiescence. Interface Focus (2014) 0.82

The switching role of β-adrenergic receptor signalling in cell survival or death decision of cardiomyocytes. Nat Commun (2014) 0.81

Bayesian learning from marginal data in bionetwork models. Stat Appl Genet Mol Biol (2011) 0.81

Robustness of cell cycle control and flexible orders of signaling events. Sci Rep (2015) 0.78

Elimination of quiescent slow-cycling cells via reducing quiescence depth by natural compounds purified from Ganoderma lucidum. Oncotarget (2017) 0.77

Principles of dynamical modularity in biological regulatory networks. Sci Rep (2016) 0.77

Linear population allocation by bistable switches in response to transient stimulation. PLoS One (2014) 0.77

Measurement and modeling of transcriptional noise in the cell cycle regulatory network. Cell Cycle (2013) 0.77

A Dynamic Gene Regulatory Network Model That Recovers the Cyclic Behavior of Arabidopsis thaliana Cell Cycle. PLoS Comput Biol (2015) 0.76

An Atlas of Network Topologies Reveals Design Principles for Caenorhabditis elegans Vulval Precursor Cell Fate Patterning. PLoS One (2015) 0.76

Are Quasi-Steady-State Approximated Models Suitable for Quantifying Intrinsic Noise Accurately? PLoS One (2015) 0.75

A Regulated Double-Negative Feedback Decodes the Temporal Gradient of Input Stimulation in a Cell Signaling Network. PLoS One (2016) 0.75

Can systems biology approach help in finding more effective treatment for acute myeloid leukemia? Syst Synth Biol (2014) 0.75

Dynamical properties of gene regulatory networks involved in long-term potentiation. Front Mol Neurosci (2015) 0.75

Systematic reverse engineering of network topologies: a case study of resettable bistable cellular responses. PLoS One (2014) 0.75

Adaptation with transcriptional regulation. Sci Rep (2017) 0.75

MicroRNA inhibition fine-tunes and provides robustness to the restriction point switch of the cell cycle. Sci Rep (2016) 0.75

c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81

Construction of a genetic toggle switch in Escherichia coli. Nature (2000) 24.02

The retinoblastoma protein and cell cycle control. Cell (1995) 20.21

The regulation of E2F by pRB-family proteins. Genes Dev (1998) 12.77

Robustness in bacterial chemotaxis. Nature (1999) 12.55

Robustness in simple biochemical networks. Nature (1997) 12.21

COPASI--a COmplex PAthway SImulator. Bioinformatics (2006) 10.57

E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science (1992) 10.28

Biological robustness. Nat Rev Genet (2004) 9.98

The segment polarity network is a robust developmental module. Nature (2000) 9.28

Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. Curr Opin Cell Biol (2002) 9.17

Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. Curr Opin Cell Biol (2003) 8.91

Multistability in the lactose utilization network of Escherichia coli. Nature (2004) 7.71

Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol (2002) 7.64

Robustness of cellular functions. Cell (2004) 6.65

Evolvability. Proc Natl Acad Sci U S A (1998) 6.34

Building a cell cycle oscillator: hysteresis and bistability in the activation of Cdc2. Nat Cell Biol (2003) 5.86

Defining network topologies that can achieve biochemical adaptation. Cell (2009) 5.49

The Rb/E2F pathway and cancer. Hum Mol Genet (2001) 4.98

Hysteresis drives cell-cycle transitions in Xenopus laevis egg extracts. Proc Natl Acad Sci U S A (2002) 4.58

Robustness of the BMP morphogen gradient in Drosophila embryonic patterning. Nature (2002) 4.21

Perspective: Evolution and detection of genetic robustness. Evolution (2003) 4.10

Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell (1994) 4.01

Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev (2000) 3.74

Variability and robustness in T cell activation from regulated heterogeneity in protein levels. Science (2008) 3.38

The E2F family: specific functions and overlapping interests. EMBO J (2004) 3.33

DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem Sci (1994) 3.32

A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91

Emergent bistability by a growth-modulating positive feedback circuit. Nat Chem Biol (2009) 2.86

Robustness of a gene regulatory circuit. EMBO J (1999) 2.53

Potential landscape and flux framework of nonequilibrium networks: robustness, dissipation, and coherence of biochemical oscillations. Proc Natl Acad Sci U S A (2008) 2.43

The restriction point of the cell cycle. Cell Cycle (2002) 2.22

Robustness and modular design of the Drosophila segment polarity network. Mol Syst Biol (2006) 2.06

Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91

The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol (1996) 1.87

A model for restriction point control of the mammalian cell cycle. J Theor Biol (2004) 1.86

miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene (2008) 1.86

Design and diversity in bacterial chemotaxis: a comparative study in Escherichia coli and Bacillus subtilis. PLoS Biol (2004) 1.78

Feedback regulation of opposing enzymes generates robust, all-or-none bistable responses. Curr Biol (2008) 1.57

Dynamics of the cell cycle: checkpoints, sizers, and timers. Biophys J (2003) 1.47

Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. EMBO J (1998) 1.39

Origin of irreversibility of cell cycle start in budding yeast. PLoS Biol (2010) 1.30

CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem (1997) 1.28

Accumulation of cyclin E is not a prerequisite for passage through the restriction point. Mol Cell Biol (2001) 1.28

The kinetic origins of the restriction point in the mammalian cell cycle. Cell Prolif (1999) 1.23

Bistable biochemical switching and the control of the events of the cell cycle. Oncogene (1997) 1.11

Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC. Mol Cell (2011) 1.03

Stochastic E2F activation and reconciliation of phenomenological cell-cycle models. PLoS Biol (2010) 1.03

Evolution of complex gene regulatory circuits by addition of refinements. Curr Biol (2010) 0.97

Robustness and fragility in the yeast high osmolarity glycerol (HOG) signal-transduction pathway. Mol Syst Biol (2009) 0.95

A mathematical description of regulation of the G1-S transition of the mammalian cell cycle. Biotechnol Bioeng (1999) 0.93

Temporal cooperativity and sensitivity amplification in biological signal transduction. Biochemistry (2008) 0.93

Single cell analysis of G1 check points-the relationship between the restriction point and phosphorylation of pRb. Exp Cell Res (2005) 0.88

Constitutive N-myc gene expression inhibits trkA mediated neuronal differentiation. Oncogene (1995) 0.81

Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56

Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45

Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99

Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69

A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61

Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45

High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92

Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78

Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67

Long-term monitoring of bacteria undergoing programmed population control in a microchemostat. Science (2005) 3.54

A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30

Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26

Engineering microbial consortia: a new frontier in synthetic biology. Trends Biotechnol (2008) 3.26

GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22

An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07

Statistical mixture modeling for cell subtype identification in flow cytometry. Cytometry A (2008) 3.06

A synthetic Escherichia coli predator-prey ecosystem. Mol Syst Biol (2008) 2.92

A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91

Emergent bistability by a growth-modulating positive feedback circuit. Nat Chem Biol (2009) 2.86

E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81

Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80

Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74

Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63

Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49

Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38

Understanding GPU Programming for Statistical Computation: Studies in Massively Parallel Massive Mixtures. J Comput Graph Stat (2010) 2.38

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37

Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32

Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23

A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22

Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91

Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89

Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76

Embracing the complexity of genomic data for personalized medicine. Genome Res (2006) 1.75

Image segmentation and dynamic lineage analysis in single-cell fluorescence microscopy. Cytometry A (2010) 1.75

Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72

Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem (2001) 1.70

Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69

Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68

The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet (2008) 1.60

Spatial Mixture Modelling for Unobserved Point Processes: Examples in Immunofluorescence Histology. Bayesian Anal (2009) 1.58

Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol (2006) 1.57

Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci U S A (2002) 1.51

Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet (2003) 1.51

Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46

The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells. J Biol Chem (2003) 1.46

Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45

Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44

Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43

A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription. Genes Dev (2004) 1.42

Balancing the decision of cell proliferation and cell fate. Cell Cycle (2009) 1.36

Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35

Combinatorial gene control involving E2F and E Box family members. EMBO J (2004) 1.35

Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet (2010) 1.34

Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci U S A (2005) 1.34

Biology by design: reduction and synthesis of cellular components and behaviour. J R Soc Interface (2007) 1.33

Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol (2004) 1.29

Prediction and uncertainty in the analysis of gene expression profiles. In Silico Biol (2002) 1.27

Optimality and robustness in quorum sensing (QS)-mediated regulation of a costly public good enzyme. Proc Natl Acad Sci U S A (2012) 1.27

Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26

Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res (2009) 1.26

Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res (2003) 1.26

Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle (2011) 1.25

Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res (2010) 1.24

Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol (2010) 1.20

An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res (2009) 1.19

Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res (2008) 1.19

Bayesian analysis of matrix normal graphical models. Biometrika (2009) 1.18

Jab1 is a specificity factor for E2F1-induced apoptosis. Genes Dev (2006) 1.17

An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer. BMC Genomics (2008) 1.14

Genomic strategies for personalized cancer therapy. Hum Mol Genet (2007) 1.14

A synthetic biology challenge: making cells compute. Mol Biosyst (2007) 1.14

Noise reduction by diffusional dissipation in a minimal quorum sensing motif. PLoS Comput Biol (2008) 1.12

Optimal tuning of bacterial sensing potential. Mol Syst Biol (2009) 1.12

Retracted Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood (2005) 1.12

Utilization of genomic signatures to identify phenotype-specific drugs. PLoS One (2009) 1.12

Temporal control of self-organized pattern formation without morphogen gradients in bacteria. Mol Syst Biol (2013) 1.11

Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci U S A (2005) 1.09